Table 1 Details of MOG antigen and PLGA + rapamycin interventions
Groups | Antigen | Conc | Administration | Rapamycin | PLGA | Others |
|---|---|---|---|---|---|---|
A | MOG1-125 | 10 mg/mL | Intraperitoneal | + | + | |
B | MOG1-125 | 10 mg/mL | Intravenous | + | + | |
C | MOG1-125 | 10 mg/mL | Subcutaneous | + | + | |
D | MOG1-125 | 1 mg/mL | Intraperitoneal | + | + | |
E | MOG1-125 | 0.1 mg/mL | Intraperitoneal | + | + | |
F | MOG1-125 | 10 mg/mL | Intraperitoneal | – | + | |
G | MOG1-125 | 0.1 mg/mL | Intraperitoneal | – | + | |
H | MOG1-125 | 10 mg/mL | Intraperitoneal | + | – | |
J | None | 10 mg/mL | Intraperitoneal | – | + | |
Positive control | – | – | – | – | – | + Fingolimod |
Negative control | – | – | – | – | – |